Boobalan Pachaiyappan

Roth Capital | Healthcare

Boobalan Pachaiyappan is an analyst from Roth Capital specializing in the Healthcare sector. Ranked #88 out of 4714 analysts, they have issued 15 stock ratings with a success rate of 96.81% and an average return of 96.07%.

With 15 ratings to date, Boobalan Pachaiyappan is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 96.81% and an average return of 96.07%, highlighting promising potential as their track record develops further.

#88

Out of 4714

15

Total Ratings

+96.81%

Success Rate

+96.07%

Average Return

Recent Ratings Analysis

ANVS

Jul 08, 2026

Target

$8.00

Current

$1.99

Performance

0.00%

Boobalan Pachaiyappan rated ANVS as Buy on Jul 08, 2026, setting a price target of 8. Shares have remained stable near 1.99, leaving the 8 target still in play.

PMN

Jul 08, 2026

Target

$19.00

Current

$13.78

Performance

0.00%

On Jul 08, 2026, PMN was given a Buy rating by Boobalan Pachaiyappan, with a target price of 19. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

COYA

Jun 05, 2026

Target

$12.00

Current

$5.36

Performance

21.27%

COYA received a Buy rating from Boobalan Pachaiyappan on Jun 05, 2026, aiming for 12. Momentum has favored the Buy call, with shares climbing from 5.36 to 5.36, rewarding those who trusted the recommendation.

CING

Mar 23, 2026

Target

$14.00

Current

$4.84

Performance

-30.16%

On Mar 23, 2026, Boobalan Pachaiyappan published a Buy outlook on CING, with a target of 14. Market action contradicted the Buy thesis, as shares slipped to 4.84.

CRVO

Mar 18, 2026

Target

$11.00

Current

$3.41

Performance

-19.58%

Boobalan Pachaiyappan on Mar 18, 2026 assigned CRVO a Buy rating, with a price target of 11. The call has struggled to gain traction, with shares losing 19.58%.

NRSN

Mar 10, 2026

Target

$3.00

Current

$0.71

Performance

-18.39%

On Mar 10, 2026, Boobalan Pachaiyappan reaffirmed NRSN with a Buy rating, targeting 3. Shares slid 18.39% despite the recommendation, highlighting downside risks.

OVID

Dec 11, 2025

Target

$3.00

Current

$2.73

Performance

65.45%

OVID was rated Buy by Boobalan Pachaiyappan on Dec 11, 2025, with a price objective of 3. A bullish response from the market helped close the gap of 0.27 to the target.

PYPD

Nov 13, 2025

Target

$9.00

Current

$5.21

Performance

45.53%

On Nov 13, 2025, Boobalan Pachaiyappan initiated coverage on PYPD with a Buy rating and target of 9. The stock’s climb of 45.53% since the call highlights the foresight in the rating.

CAPR

Nov 12, 2025

Target

$13.00

Current

$22.25

Performance

279.05%

Boobalan Pachaiyappan issued a Buy recommendation for CAPR on Nov 12, 2025, price target set at 13. Investors following the Buy call captured upside momentum, with shares now at 22.25.

RNA

Sep 17, 2025

Target

$62.00

Current

$13.37

Performance

-66.63%

On Sep 17, 2025, RNA was evaluated by Boobalan Pachaiyappan, who gave a Buy rating and target of 62. Investors saw limited payoff as shares fell short of the 62 target.

RVPH

Aug 18, 2025

Target

$3.00

Current

$0.53

Performance

-94.90%

Boobalan Pachaiyappan rated RVPH as Buy on Aug 18, 2025, setting a price target of 3. The stock has underperformed, dropping 94.90% despite the bullish target of 3.

LGVN

Aug 15, 2025

Target

$3.00

Current

$0.64

Performance

-15.39%

On Aug 15, 2025, LGVN was given a Buy rating by Boobalan Pachaiyappan, with a target price of 3. Despite the Buy call, shares fell from 0.643 to 0.643, challenging the optimistic stance.

GANX

Aug 13, 2025

Target

$6.00

Current

$1.79

Performance

15.48%

GANX received a Buy rating from Boobalan Pachaiyappan on Aug 13, 2025, aiming for 6. Momentum has favored the Buy call, with shares climbing from 1.79 to 1.79, rewarding those who trusted the recommendation.

VRNA

Jun 18, 2025

Target

$116.00

Current

$106.91

Performance

17.59%

On Jun 18, 2025, Boobalan Pachaiyappan published a Buy outlook on VRNA, with a target of 116. Shares gained 17.59%, underscoring the accuracy of the bullish outlook toward 116.

TRDA

Dec 05, 2024

Target

$29.00

Current

$7.32

Performance

-63.98%

Boobalan Pachaiyappan on Dec 05, 2024 assigned TRDA a Buy rating, with a price target of 29. The call has struggled to gain traction, with shares losing 63.98%.

Frequency Asked Questions

Who is Boobalan Pachaiyappan?

Boobalan Pachaiyappan is an analyst from Roth Capital specializing in the Healthcare sector.

What is Boobalan Pachaiyappan's success rate?

Boobalan Pachaiyappan currently has a success rate of +96.81%.

How many ratings has Boobalan Pachaiyappan issued?

Boobalan Pachaiyappan has issued 15 stock ratings so far.

What is the average return of Boobalan Pachaiyappan's calls?

Their stock ratings have generated an average return of +96.07%.

What is Boobalan Pachaiyappan's ranking?

Boobalan Pachaiyappan is ranked #88 out of 4714 analysts.

What types of ratings does Boobalan Pachaiyappan give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Boobalan Pachaiyappan?

You can follow Boobalan Pachaiyappan by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Boobalan Pachaiyappan?

Their latest rating was a Buy on ANVS issued on 2026-07-08.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep